Pain and Inflammation Research
Although separate conditions, pain and inflammation are nearly always associated with each other. Pain is defined by the International Association for the Study of Pain (IASP) as 'an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage'. Inflammation is the tissue's immunologic response to injury, characterized by mobilization of white blood cells and antibodies, swelling, and fluid accumulation.
Pain and Inflammation Research Products Areas
Products for Pain and Inflammation Research - Page 15
- Cat.No. Product Name Information/Activity
-
BCC3602
KN-62
KN-62 is a selective and potent inhibitor of calmodulin-dependent protein kinase II (CaMK-II) with IC50 of 0.9 μM, KN-62 also displays noncompetitive antagonism at P2X7 receptors in HEK293 cells, with an IC50 value of approximately 15 nM.
-
BCC6985
NF 023
104869-31-0
-
BCC7404
NF 110
111150-22-2
-
BCC7367
NF 157
NF157 is a highly selective nanomolar P2Y11 antagonist with a pKi of 7.35. The IC50s are 463 nM, 1811 µM, 170 µM for P2Y11 (Ki=44.3 nM), P2Y1 (Ki=187 µM), P2Y2 (Ki=28.9 µM), respectively. NF157, significantly reduces expression of metalloproteinase (MMP)-3, MMP-13, can be used in the treatment of osteoarthritis (OA).
-
BCC6964
NF 279
202983-32-2
-
BCC7043
NF 449
Highly selective P2X<sub>1</sub> antagonist
-
BCC6725
PPADS tetrasodium salt
PPADS tetrasodiuma is a non-selective P2X receptor antagonist. PPADS tetrasodiuma blocks recombinant P2X1, -2, -3, -5 with IC50s ranging from 1 to 2.6 μM. PPADS tetrasodiuma blocks native P2Y2-like (IC50~0.9 mM) and recombinant P2Y4 (IC50~15 mM) receptors. PPADS tetrasodiuma is an inhibitor of the reverse mode of the Na/Ca²⁺exchanger in guinea pig airway smooth muscle.
-
BCC6749
iso-PPADS tetrasodium salt
P2X antagonist
-
BCC7015
PPNDS
1021868-77-8
-
BCC7276
Ro 0437626
134362-79-1


